Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD).The candidate is being jointly developed by Regeneron and Sanofi. It is currently in clinical development programs for chronic rhinosinusitis with nasal polyps (phase III), non-cystic fibrosis bronchiectasis (phase II) and chronic rhinosinusitis without nasal polyps (phase II).Year to date, ...

赛诺菲和再生元正在评估数据，并将与监管机构进行讨论。赛诺菲研发部负责人Houman Ashrafian在声 明中表示，这两项研究的结果值得进一步探索，以充分了解该药物如何与一种名为IL33的蛋白质相互作 用。IL33会导致这种复杂疾病的炎症。戒烟者肺部的IL33水平会升高。 分析师们密切关注Itepekimab的试验数据，因为赛诺菲重磅药物Dupixent的专利即将到期。Dupixent是一 种被批准用于治疗包括慢性阻塞性肺病在内的多种疾病的药物，它帮助推动了赛诺菲的增长。葛兰素史 克等其他制药商也在研发治疗慢性阻塞性肺病的药物。葛兰素史克的Nucala本月早些时候在美国被批准 用于治疗慢性阻塞性肺病。 Bloomberg Intelligence分析师John Murphy表示，Itepekimab试验结果好坏参半，这是一个重大挫折，且 意味着药物研发流程要至少推迟3年。他还表示："许多慢性阻塞性肺病药物最初只是在详细分析中未能 显示对部分患者有益，但人们对这种潜在的药物寄予厚望。其他用途仍在研究中。" 智通财经APP获悉，周五美股盘前，赛诺菲(SNY.US)股价下跌6.17%，再生元(REGN.US)股价 ...

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition bolsters Sanofi’s ambition to become the foremost immunology company and broadens the company’s leading immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. The potential first-in ...

市场消息：赛诺菲(SNY.O)签署协议，将疫苗生产技术转让给越南。 ...

Nucala和Dupixent等生物药物为COPD患者提供了更多治疗选择，到目前为止，这些患者的治疗主要依 吸入器、类固醇和专门的运动项目等治疗方法。 Murphy表示，市场营销"将尝试将其中一种药物与另一种药物进行对比"，但考虑到替代方案有限，两 种药物都将获得"显著的市场认可" 。Nucala每四周注射一次，而Dupixent每两周注射一次。 葛兰素史克首席商务官Luke Miels在4月份的财报电话会议上表示，公司认为Nucala与Dupixent竞争非常 激烈。他表示，葛兰素史克一直在密切关注Dupixent的上市情况，包括赛诺菲的市场准入、患者基础以 及人们使用该药物的原因。 Miels在另一场会议上表示，该公司对Nucala的初始销售持谨慎态度。该药物将主要由肺科医生开具用 于治疗COPD，这些医生会向一小部分患者推荐生物药物。他表示："将会有一段时间的实验、应用和 培训。" 智通财经APP获悉，葛兰素史克(GSK.US)治疗一种致命肺部疾病的药物获得美国批准，加剧了与竞争 对手赛诺菲(SNY.US)的竞争。据悉，美国食品和药物管理局(FDA)批准葛兰素史克的Nucala作为部分慢 性阻塞性肺病( ...

MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest st ...

French pharma giant Sanofi (SNY) recently announced that it has agreed to acquire Massachusetts-based biotech Vigil Neuroscience (VIGL) for a total equity value of around $470 million.The acquisition will boost Sanofi’s neurology pipeline by adding Vigil’s investigational oral small-molecule TREM2 agonist, VG-3927, which is being developed as a potential treatment for Alzheimer’s disease.A phase II study will evaluate VG-3927 in Alzheimer’s disease.TREM2 is a protein key for immune cell function, particular ...

在全球老龄化趋势下，阿尔茨海默病等神经退行性疾病治疗领域存在巨大未满足医疗需求，赛诺菲正通 过"自主研发+精准并购"双轮驱动，构建差异化的中枢神经系统药物管线。 此次收购聚焦神经病学领域，这是赛诺菲四大核心战略疾病方向之一。赛诺菲方面表示，通过整合Vigil 的阿尔茨海默病研发管线，将强化公司在神经退行性疾病领域的早期研发布局。目前VG-3927正处于二 期临床研究阶段，赛诺菲计划加速推进该候选药物的临床开发进程。 根据交易条款，赛诺菲将以每股8美元的现金预付对价完成收购，较Vigil周三收盘价溢价236%。协议还 设定额外里程碑条款：若Vigil核心在研产品——阿尔茨海默病治疗药物VG-3927在规定期限内实现首次 商业化销售，其股东将获得每股2美元的追加现金支付。 法国制药巨头赛诺菲(SNY.US)宣布，将以4.7亿美元现金收购临床阶段生物技术公司Vigil Neuroscience(VIGL.US)，若后续研发里程碑达成，收购总价可能升至6亿美元。受该消息刺激，Vigil股 价在美股周四盘前交易时段暴涨241%，而赛诺菲股价保持平稳。 值得关注的是，此次收购并非赛诺菲首次布局Vigil。公开资料显示，赛 ...

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s disease – - Companies expect transaction to close in third quarter of 2025 - WATE ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances Sanofi’s early-stage pipeline and ...